Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when Eloralintide 10mg crosses your target, drops, or sets a new tracked low—without daily noise.

Public product evidence6 certificate records mentioning this compound or product name4 provider-linked · 5 exact product matches

Status

Investigational

This compound has a genuine development or study trail, but it is not an approved routine drug.

Research area

Metabolic / incretin research

Primary research area: Metabolic. Also surfaces under Hormone for browsing and discovery.

Aliases

LY3841136

Signal depth

Medium

No FDA label signal · 21 trials · 8 PubMed results

Promising

Research evidence

Eloralintide has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

Eloralintide has 19 name-matched clinical trials (highest phase: Phase 3) and 8 PubMed-indexed publications and is not FDA-approved. 1 trial has posted results.

Human data

Phase 3

Trial quality

Large RCT

Outcomes

Clinical outcomes

Replication

Meta-analysis

Literature

Emerging

PHASE3 · RandomizedA Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes PHASE3 · RandomizedA Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin The Lancet · 32 citationsEloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial Molecular Metabolism · 18 citationsEloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept Diabetes Obesity and Metabolism · 4 citationsEloralintide, a selective, long‐acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept Journal ArticleBeyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs.

Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What eloralintide is

Eloralintide is Eli Lilly’s investigational selective amylin receptor agonist for obesity and overweight.

Why it matters

It gives the library a major amylin-only obesity candidate, which helps separate it from dual-pathway agents like amycretin or petrelintide combination narratives. The fact that it has already advanced into Phase 3 makes it much more than a speculative name.

Regulatory context

Eloralintide is not FDA approved. It sits firmly in the late-stage investigational category.

Practical reading note

This is one of the better examples of why not every important obesity peptide is another GLP-1 story. Amylin-focused drugs are now a real lane of their own.